Table 2.

Examples of clinical trials using targeted therapies in glioblastoma.

	Trial	Molecular Target	Therapy	Status
Cell signalling pathways	NCT01339052	PI3K	Buparlisib	Completed (phase II)
	NCT00943826	VEGF	Bevacizumab + TMZ	Completed (phase III)
	NCT01019434	mTOR	Temsirolimus + RT	Completed (phase II)
	NCT05222802	EGFR	ERAS-801	Recruiting (phase I)
	NCT02981940	CDK4/6	Abemaciclib	Active, not recruiting (phase II)
	NCT01268566	PDGFR	MEDI-575	Completed (phase II)
	NCT01632228	MET	Onartuzumab	Completed (phase II)
	NCT05376800	MDM2	Brigimadlin	Recruiting (phase 0/Ia)
	NCT01975701	FGFR	BGJ398	Completed (phase II)
	NCT02340156	p53	SGT-53 + TMZ	Terminated (phase II)
	NCT02345824	CDK4/6	Ribociclib	Unknown status (phase I)
	NCT04121455	CXCL12	NOX-A12 + RT	Active, not recruiting (phase I/II)
	NCT06102525	hTERT	RZ-001 + Valganciclovir	Not yet recruiting (phase I/IIa)
	NCT01582269	TGF-β	Galunisertib	Active, not recruiting (phase II)
Tumour cell metabolism	NCT04825275	HK2—glucose metabolism	Posaconazole	Recruiting (phase 0)
	NCT04587830	Arginine metabolism	ADI-PEG 20 + RT + TMZ	Recruiting (phase Ib)
	NCT03032484	FASN—lipid metabolism	TVB-2640 + Bevacizumab	Completed (phase II)
	NCT04869449	HK2—glucose metabolism	Ketoconazole	Recruiting (early phase I)
	NCT02029573	HMGCR—cholesterol Metabolism	Atorvastatin + RT + TMZ	Completed (phase II)